Table 2: Risk of Alzheimer’s disease, non-Alzheimer dementia, and all-cause dementia among T2DM patients who regularly use aspirin.

Study subjectsAll-cause dementia
Aspirin statusMean daily dose (mg)Dementia cases/totalUnadjusted HR (95% CI)p valueAdjusted HR
(95% CI)
p value

No aspirin360/10720Reference (N/A)Reference (N/A)
Regular user117/28761.42 (1.15–1.75)0.0011.45 (1.15–1.84)0.002
 Cohort 1<4011/5220.55 (0.30–1.00)0.0500.48 (0.26–0.89)0.019
 Cohort 240–7939/10031.33 (0.95–1.85)0.0961.47 (1.03–2.09)0.033
 Cohort 3≥8067/13512.05 (1.57–2.66)<0.0012.35 (1.75–3.15)<0.001

Study subjectsAlzheimer’s disease
Aspirin statusMean daily dose (mg)Dementia
cases/total
Unadjusted HR
(95% CI)
p valueAdjusted HR
(95% CI)
p value

No aspirin308/10668Reference (N/A)Reference (N/A)
Regular user93/28521.33 (1.06–1.68)0.0161.37 (1.05–1.78)0.019
 Cohort 1<4010/5210.58 (0.31–1.10)0.0940.51 (0.27–0.97)0.041
 Cohort 240–7928/9921.13 (0.77–1.66)0.5451.27 (0.84–1.91)0.257
 Cohort 3≥8055/13391.99 (1.49–2.66)<0.0012.26 (1.64–3.12)<0.001

Study subjectsNon-Alzheimer dementia
Aspirin statusMean daily dose (mg)Dementia
cases/total
Unadjusted HR
(95% CI)
p valueAdjusted HR
(95% CI)
p value

No aspirin52/10412Reference (N/A)Reference (N/A)
Regular user24/27831.94 (1.19–3.16)0.0081.91 (1.09–3.36)0.025
 Cohort 1<401/5120.34 (0.05–2.46)0.2860.28 (0.04–2.05)0.209
 Cohort 240–7911/9752.49 (1.29–4.78)0.0062.54 (1.23–5.24)0.012
 Cohort 3≥8012/12962.42 (1.29–4.57)0.0062.95 (1.44–6.05)0.003

Mean daily dose (mg) = cumulative doses starting from the regular taking drug date to the end of observation date/days between the start regular taking drug date and the end of observation date.
Adjust age group, gender, CCI group, stroke types, antidiabetic drugs, statins, and hypertensive drugs.
HR: hazard ratio; CI: confidence interval; T2DM: type 2 diabetes mellitus.